MDACC Study No:2010-0788 ( NCT No: NCT01289457)
Title:Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Principal Investigator:Elias Jabbour
Treatment Agent:Clofarabine; Cytarabine; Fludarabine; Idarubicin
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
clofarabine, idarubicin, and cytarabine, or the combination of fludarabine,
idarubicin, and cytarabine can help control AML and MDS. The safety of these
study drug combinations will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Clofarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-4764
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults